In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as LYC Healthcare Berhad has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KLSE:LYC - Analysts future estimates and past financials data (MYR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2026	134	-23	24	24	N/A
12/31/2025	135	-21	17	20	N/A
9/30/2025	139	-20	31	34	N/A
6/30/2025	148	-18	40	43	N/A
3/31/2025	156	-17	23	29	N/A
12/31/2024	156	-19	20	23	N/A
9/30/2024	151	-21	17	21	N/A
6/30/2024	142	-22	6	9	N/A
3/31/2024	129	-21	5	11	N/A
12/31/2023	121	-17	-11	-4	N/A
9/30/2023	108	-17	-4	2	N/A
6/30/2023	98	-17	-7	0	N/A
3/31/2023	92	-19	2	5	N/A
12/31/2022	86	-12	21	19	N/A
9/30/2022	84	-12	3	5	N/A
6/30/2022	74	-11	-1	2	N/A
3/31/2022	65	-9	-3	0	N/A
12/31/2021	58	-11	-10	-3	N/A
9/30/2021	44	-12	-4	-1	N/A
6/30/2021	35	-12	-2	1	N/A
3/31/2021	26	-12	-6	-2	N/A
12/31/2020	16	-14	-8	3	N/A
9/30/2020	13	-12	-10	0	N/A
6/30/2020	12	-11	-12	-1	N/A
3/31/2020	12	-10	-12	-1	N/A
12/31/2019	12	-8	N/A	-7	N/A
9/30/2019	10	-8	N/A	-4	N/A
6/30/2019	6	-8	N/A	-4	N/A
3/31/2019	8	-8	N/A	-4	N/A
12/31/2018	6	-7	N/A	-1	N/A
9/30/2018	6	-6	N/A	-3	N/A
6/30/2018	7	-4	N/A	-3	N/A
3/31/2018	6	-3	N/A	-2	N/A
3/31/2017	33	-2	N/A	-2	N/A
9/30/2016	35	-1	N/A	-4	N/A
6/30/2016	39	-1	N/A	-1	N/A
3/31/2016	42	-2	N/A	-1	N/A
12/31/2015	40	-2	N/A	-3	N/A
9/30/2015	40	-2	N/A	0	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if LYC's forecast earnings growth is above the savings rate (3.8%).

Earnings vs Market: Insufficient data to determine if LYC's earnings are forecast to grow faster than the MY market

High Growth Earnings: Insufficient data to determine if LYC's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if LYC's revenue is forecast to grow faster than the MY market.

High Growth Revenue: Insufficient data to determine if LYC's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if LYC's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/08/06 12:06
End of Day Share Price	2026/08/06 00:00
Earnings	2026/03/31
Annual Earnings	2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

LYC Healthcare Berhad is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Wei Soong	RHB Investment Bank

LYC Healthcare Berhad Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

LYC Healthcare Berhad, Annual General Meeting, Sep 28, 2026

LYC Healthcare Berhad, Annual General Meeting, Sep 29, 2025

LYC Healthcare Berhad Announces the Resignation of Lee Chin Wen as Joint Secretary, Effective 4 August 2025

New major risk - Share price stability

It's Down 27% But LYC Healthcare Berhad (KLSE:LYC) Could Be Riskier Than It Looks

New major risk - Market cap size

LYC Healthcare Berhad has filed a Follow-on Equity Offering in the amount of MYR 1.529199 million.

Third quarter 2025 earnings released: RM0.004 loss per share (vs RM0.006 loss in 3Q 2024)

Investors Aren't Entirely Convinced By LYC Healthcare Berhad's (KLSE:LYC) Revenues

New major risk - Share price stability

Second quarter 2025 earnings released: RM0.004 loss per share (vs RM0.007 loss in 2Q 2024)

Is LYC Healthcare Berhad (KLSE:LYC) Weighed On By Its Debt Load?

LYC Healthcare Berhad Appoints Kong Sin Seng as Independent and Non Executive Chairman of Audit Committee

Wong Chew Weng agreed to acquire an additional 55% stake in Elite Dental Team Sdn Bhd from LYC Healthcare Berhad (KLSE:LYC) for MYR 6.5 million.

LYC Healthcare Berhad Approves Audit Committee Be Changed to Audit and Risk Management Committee, Effective September 28, 2024

Shareholders May Be More Conservative With LYC Healthcare Berhad's (KLSE:LYC) CEO Compensation For Now

Take Care Before Diving Into The Deep End On LYC Healthcare Berhad (KLSE:LYC)

Full year 2024 earnings released: RM0.029 loss per share (vs RM0.035 loss in FY 2023)

LYC Healthcare Berhad, Annual General Meeting, Sep 27, 2024

Is LYC Healthcare Berhad (KLSE:LYC) Using Too Much Debt?

Full year 2024 earnings released: RM0.03 loss per share (vs RM0.035 loss in FY 2023)

New minor risk - Share price stability

LYC Healthcare Berhad (KLSE:LYC) Doing What It Can To Lift Shares

Lyc Healthcare Berhad Appoints Chong Sook Peng as Chief Financial Officer

Third quarter 2024 earnings released: RM0.006 loss per share (vs RM0.007 loss in 3Q 2023)

LYC Healthcare Berhad Announces Resignation of Mr. Cheah SEK Hon as Chief Financial Officer , Effective from 28 April 2024

LYC Healthcare Berhad Announces Resignation of Encik Ahmad Rafique Bin Mat Tahir as Chief Operating Officer, Effective 19 February.2024

Second quarter 2024 earnings released: RM0.006 loss per share (vs RM0.009 loss in 2Q 2023)

LYC Healthcare Berhad has filed a Follow-on Equity Offering in the amount of MYR 12.804571 million.

New minor risk - Share price stability

Does LYC Healthcare Berhad (KLSE:LYC) Have A Healthy Balance Sheet?

LYC Healthcare Berhad's (KLSE:LYC) CEO Compensation Is Looking A Bit Stretched At The Moment

Full year 2023 earnings released: RM0.035 loss per share (vs RM0.021 loss in FY 2022)

LYC Healthcare Berhad, Annual General Meeting, Sep 21, 2023

Is LYC Healthcare Berhad (KLSE:LYC) Using Too Much Debt?

Full year 2023 earnings released: RM0.035 loss per share (vs RM0.021 loss in FY 2022)

LYC Healthcare Berhad Appoints Poh Zuan Yin as Independent and Non Executive Member of Audit Committee

LYC Healthcare Berhad (KLSE:LYC) acquired 55% stake in Elite Dental Team Sdn Bhd from Kenneth Wong Pak Ken, Wong Chew Weng, Carmen Yuen Chia-Wen, Yee Xin Le and Sylvia Lim Sze Wei.

Is LYC Healthcare Berhad (KLSE:LYC) A Risky Investment?

Third quarter 2023 earnings released: RM0.007 loss per share (vs RM0.007 loss in 3Q 2022)

LYC Healthcare Berhad's (KLSE:LYC) Returns On Capital Are Heading Higher

Second quarter 2023 earnings released: RM0.009 loss per share (vs RM0.007 loss in 2Q 2022)

It's Unlikely That The CEO Of LYC Healthcare Berhad (KLSE:LYC) Will See A Huge Pay Rise This Year

Here's Why LYC Healthcare Berhad (KLSE:LYC) Is Weighed Down By Its Debt Load

LYC Healthcare Berhad announced a financing transaction

Full year 2022 earnings released: RM0.021 loss per share (vs RM0.033 loss in FY 2021)

LYC Healthcare Berhad, Annual General Meeting, Sep 22, 2022

LYC Healthcare Berhad (KLSE:LYC) entered into a conditional share sale agreement to acquire a 55% stake in Elite Dental Team Sdn Bhd from Kenneth Wong Pak Ken, Wong Chew Weng, Carmen Yuen Chia-Wen, Yee Xin Le and Sylvia Lim Sze Wei for MYR 5.5 million.

LYC Healthcare Berhad Announces Appointment of Mr. Cheah SEK Hon as Chief Financial Officer

Full year 2022 earnings: EPS and revenues miss analyst expectations

Investors Will Want LYC Healthcare Berhad's (KLSE:LYC) Growth In ROCE To Persist

LYC Healthcare Berhad (KLSE:LYC) agreed to acquire Tao Global Ventures Sdn Bhd from Dinesh A/L Kanasen and Sarahanna A/P Selvarajah for RMB 4 million.

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Does LYC Healthcare Berhad (KLSE:LYC) Have A Healthy Balance Sheet?

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2021 earnings released: RM0.033 loss per share (vs RM0.029 loss in FY 2020)

Is LYC Healthcare Berhad (KLSE:LYC) Using Too Much Debt?

Full year 2021 earnings released: RM0.032 loss per share (vs RM0.029 loss in FY 2020)

How Should Investors React To LYC Healthcare Berhad's (KLSE:LYC) CEO Pay?

Third quarter 2021 earnings released: RM0.013 loss per share (vs RM0.006 loss in 3Q 2020)

Non-Independent Non-Executive Director has left the company

LYC Healthcare Berhad Announces Resignation of Josephie Sui Sze Pin as Non Independent and Non Executive Member of Remuneration Committee

New 90-day low: RM0.25

New 90-day low: RM0.29

New 90-day low: RM0.30

New 90-day low: RM0.32

Second quarter 2021 earnings released: RM0.008 loss per share

LYC Healthcare Berhad (KLSE:LYC) acquired remaining 49% stake in LYC Cosmetic & Aesthetic Sdn Bhd from Xing Dao International Pte. Ltd for MYR 0.05 million.

New 90-day low: RM0.33

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies

Company Analysis and Financial Data Status